KAPA: ENV105 leads a robust pipeline targeting cancer resistance, with strong early clinical results and funding
Focused on overcoming cancer drug resistance and immune suppression, the company advances a pipeline led by ENV105, now in Phase 2 for prostate cancer and Phase 1 for lung cancer. Early clinical data show promising efficacy, supported by strong funding, partnerships, and intellectual property.Origi…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.